Cargando…

放疗时间选择对局限期小细胞肺癌预后影响的meta分析

BACKGROUND AND OBJECTIVE: Although evidence for a significant survival benefit of chest radiotherapy has been proven, no conclusion could be drawn regarding the optimal timing of chest radiation. The aim of this study is to explore whether the timing of chest radiation may influence the survival of...

Descripción completa

Detalles Bibliográficos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 中国肺癌杂志编辑部 2010
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6000350/
https://www.ncbi.nlm.nih.gov/pubmed/20840819
http://dx.doi.org/10.3779/j.issn.1009-3419.2010.09.10
_version_ 1783331693191495680
collection PubMed
description BACKGROUND AND OBJECTIVE: Although evidence for a significant survival benefit of chest radiotherapy has been proven, no conclusion could be drawn regarding the optimal timing of chest radiation. The aim of this study is to explore whether the timing of chest radiation may influence the survival of the patients with limited-stage small-cell lung cancer (LS-SCLC) by performing a literature-based meta-analysis. METHODS: By searching Medline, CENTRAL (the Cochrane central register of controlled trials), CBM, and CNKI, et al, we collected both domestic and overseas published documents about randomized trials comparing different timing chest radiotherapy in patients with LS-SCLC. Early chest radiation was regarded as beginning within 30 days after the start of chemotherapy. Random or fixed effect models were applied to conduct meta-analysis on the trials. The combined odds ratio (OR) and the 95% confidence interval (CI) were calculated to estimate the mortality in 2 or 3 years and toxicity of the two treatments. The statistical heterogeneity was determined by cochran's Chi-square test (Q test). The Begg' test was used to determine the publication bias. RESULTS: Six trials that included a total of 1 189 patients were analyzed in the meta-analysis 587 patients were in the early radiation group and 602 patients were in the late radiation group. Considering all 6 eligible trials, the overall survival at 2/3 years was not significantly different between early and late chest radiation (OR=0.78, 95%CI: 0.55-1.05, Z=1.68, P=0.093). For the toxicity, no obvious difference was observed for early chest radiotherapy compared with late irradiation in pneumonitis (OR=1.93, 95%CI: 0.97-3.86, P=0.797), esophagitis (OR=1.43, 95%CI: 0.95-2.13, P=0.572) and thrombocytopenia (OR=1.23, 95%CI: 0.88-1.77, P=0.746), respectively. CONCLUSION: No statistical difference was observed in 2/3 years survival and toxicity, including pneumonitis, esophagitis and thrombocytopenia, between early radiation and late radiotherapy in LS-SCLC.
format Online
Article
Text
id pubmed-6000350
institution National Center for Biotechnology Information
language English
publishDate 2010
publisher 中国肺癌杂志编辑部
record_format MEDLINE/PubMed
spelling pubmed-60003502018-07-06 放疗时间选择对局限期小细胞肺癌预后影响的meta分析 Zhongguo Fei Ai Za Zhi 临床研究 BACKGROUND AND OBJECTIVE: Although evidence for a significant survival benefit of chest radiotherapy has been proven, no conclusion could be drawn regarding the optimal timing of chest radiation. The aim of this study is to explore whether the timing of chest radiation may influence the survival of the patients with limited-stage small-cell lung cancer (LS-SCLC) by performing a literature-based meta-analysis. METHODS: By searching Medline, CENTRAL (the Cochrane central register of controlled trials), CBM, and CNKI, et al, we collected both domestic and overseas published documents about randomized trials comparing different timing chest radiotherapy in patients with LS-SCLC. Early chest radiation was regarded as beginning within 30 days after the start of chemotherapy. Random or fixed effect models were applied to conduct meta-analysis on the trials. The combined odds ratio (OR) and the 95% confidence interval (CI) were calculated to estimate the mortality in 2 or 3 years and toxicity of the two treatments. The statistical heterogeneity was determined by cochran's Chi-square test (Q test). The Begg' test was used to determine the publication bias. RESULTS: Six trials that included a total of 1 189 patients were analyzed in the meta-analysis 587 patients were in the early radiation group and 602 patients were in the late radiation group. Considering all 6 eligible trials, the overall survival at 2/3 years was not significantly different between early and late chest radiation (OR=0.78, 95%CI: 0.55-1.05, Z=1.68, P=0.093). For the toxicity, no obvious difference was observed for early chest radiotherapy compared with late irradiation in pneumonitis (OR=1.93, 95%CI: 0.97-3.86, P=0.797), esophagitis (OR=1.43, 95%CI: 0.95-2.13, P=0.572) and thrombocytopenia (OR=1.23, 95%CI: 0.88-1.77, P=0.746), respectively. CONCLUSION: No statistical difference was observed in 2/3 years survival and toxicity, including pneumonitis, esophagitis and thrombocytopenia, between early radiation and late radiotherapy in LS-SCLC. 中国肺癌杂志编辑部 2010-09-20 /pmc/articles/PMC6000350/ /pubmed/20840819 http://dx.doi.org/10.3779/j.issn.1009-3419.2010.09.10 Text en 版权所有©《中国肺癌杂志》编辑部2010 https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY 3.0) License. See: https://creativecommons.org/licenses/by/3.0/
spellingShingle 临床研究
放疗时间选择对局限期小细胞肺癌预后影响的meta分析
title 放疗时间选择对局限期小细胞肺癌预后影响的meta分析
title_full 放疗时间选择对局限期小细胞肺癌预后影响的meta分析
title_fullStr 放疗时间选择对局限期小细胞肺癌预后影响的meta分析
title_full_unstemmed 放疗时间选择对局限期小细胞肺癌预后影响的meta分析
title_short 放疗时间选择对局限期小细胞肺癌预后影响的meta分析
title_sort 放疗时间选择对局限期小细胞肺癌预后影响的meta分析
topic 临床研究
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6000350/
https://www.ncbi.nlm.nih.gov/pubmed/20840819
http://dx.doi.org/10.3779/j.issn.1009-3419.2010.09.10
work_keys_str_mv AT fàngliáoshíjiānxuǎnzéduìjúxiànqīxiǎoxìbāofèiáiyùhòuyǐngxiǎngdemetafēnxī
AT fàngliáoshíjiānxuǎnzéduìjúxiànqīxiǎoxìbāofèiáiyùhòuyǐngxiǎngdemetafēnxī
AT fàngliáoshíjiānxuǎnzéduìjúxiànqīxiǎoxìbāofèiáiyùhòuyǐngxiǎngdemetafēnxī
AT fàngliáoshíjiānxuǎnzéduìjúxiànqīxiǎoxìbāofèiáiyùhòuyǐngxiǎngdemetafēnxī
AT fàngliáoshíjiānxuǎnzéduìjúxiànqīxiǎoxìbāofèiáiyùhòuyǐngxiǎngdemetafēnxī
AT fàngliáoshíjiānxuǎnzéduìjúxiànqīxiǎoxìbāofèiáiyùhòuyǐngxiǎngdemetafēnxī
AT fàngliáoshíjiānxuǎnzéduìjúxiànqīxiǎoxìbāofèiáiyùhòuyǐngxiǎngdemetafēnxī
AT fàngliáoshíjiānxuǎnzéduìjúxiànqīxiǎoxìbāofèiáiyùhòuyǐngxiǎngdemetafēnxī
AT fàngliáoshíjiānxuǎnzéduìjúxiànqīxiǎoxìbāofèiáiyùhòuyǐngxiǎngdemetafēnxī